VerifiedRx Podcast By Vizient Center for Pharmacy Practice Excellence cover art

VerifiedRx

VerifiedRx

By: Vizient Center for Pharmacy Practice Excellence
Listen for free

Get 3 months for $0.99 a month
Delivering short doses of insight for hospitals’ frontline pharmacy professionals, the Vizient pharmacy team brings together experts to verify best practices for navigating today’s pharmacy practice challenges and accelerating career growth. It’s a prescription for success, delivered by the Vizient Center for Pharmacy Practice Excellence.Copyright 2025 All rights reserved. Economics Hygiene & Healthy Living Management Management & Leadership Physical Illness & Disease Science
Episodes
  • Pipeline 2026: The Movers, the Shapers, & What Matters

    Pipeline 2026: The Movers, the Shapers, & What Matters
    Nov 25 2025
    If you're wondering which therapies may influence care delivery, budgets, and decision making in 2026, the pipeline offers an early preview and it points to a year defined by innovation. We're seeing new first in class treatments, thoughtful next generation agents, and a biosimilar market where fewer launches are offset by important competitive shifts driven by recent approvals. John Schoen and Heather Pace from the Center for Pharmacy Practice Excellence join Stacy Lauderdale, Associate Vice President of Evidence-Based Medicine and Drug Information and your Verified RX program host to highlight pipeline agents worth watching and discuss what they may mean for care delivery and spend management in the year ahead. Guest speakers: John Schoen, PharmD, BCPS  Senior Clinical Manager of Drug Information   Vizient Center for Pharmacy Practice Excellence  Heather Pace, PharmD Senior Clinical Manager of Drug Information   Vizient Center for Pharmacy Practice Excellence  Host:  Stacy Lauderdale, PharmD, BCPS  Associate Vice President Vizient Center for Pharmacy Practice Excellence Show Notes: 01:01 — Episode Scope The focus is non-CGT therapies; CGT pipeline will be covered in Part 2. 01:50 — Therapeutic Areas With the Most Approvals Oncology leads the pipeline.Others include infectious disease, neurology, rare disease, endocrine, hepatology, dermatology, and rheumatology. 02:37 — Biosimilars in 2026: Momentum or Headwinds? Discussion of potential “biosimilar void”—only 10% of expiring biologic patents have biosimilars in development.Emerging role of PBM private-label biosimilars. 03:51 — FDA Draft Guidance on Interchangeability FDA exploring interchangeable designation for all biosimilars.Potential shift away from clinical efficacy studies in favor of analytical comparisons.Guidance still in draft and open for public comment. 05:34 — John’s Top Picks for First-in-Class Agents 06:11 — Orviglance First manganese-based, oral MRI contrast agent.Advantages for patients with kidney impairment.Used for liver imaging. 06:20 — Why Non-Gadolinium Matters Lower risk of nephrogenic systemic fibrosis. 06:46 — Tabelecleucel First allogeneic EBV-specific T-cell therapy.For EBV-positive PTLD post-transplant.Could become new standard of care. 07:42 — Tanruprubart First therapy specifically for severe Guillain-Barré Syndrome (GBS). Shows improved outcomes over IVIG and plasma exchange. 08:20 — Comparing to Standard of Care Review of improved real-world data outcomes. 09:03 — Therapies That May Shift Care Delivery 09:32 — Icotrokinra: First oral IL-23 antagonist for plaque psoriasis. 10:00 — Insulin Icodec First once-weekly basal insulin for type 2 diabetes.Resubmitted after safety concerns in type 1 diabetes. 10:59 — Honorable Mentions Camizestrant SERD for ER+/HER2– metastatic breast cancer. Ensitrelvir (COVID-19) Oral option for pre-exposure prophylaxis.Also being evaluated for treatment. Doravirine + Islatravir (HIV) Introduces new NRTTI class. Cefepime + Zidebactam Active against metallo-β-lactamase–producing organisms. 14:05 — Key Biosimilar Launches Omalizumab (Xolair) First biosimilars in asthma/allergy space. Aflibercept (Eylea) High competition expected pending litigation. Pertuzumab (Perjeta) First biosimilar anticipated in oncology. 15:31 — Biosimilars Approved in 2025, Impacting 2026 Ustekinumab (Stelara): first full year of competitionDenosumab (Prolia/Xgeva): 10–15 biosimilars expectedEculizumab (Soliris): notable for rare disease market entry 17:17 — John’s Closing Thoughts Strong mix of first-in-class advances and next-gen convenience therapies. 17:36 — Heather’s Closing Thoughts 2026 will focus on speed and scale after the 2025 biosimilar wave.Pharmacists pivotal in ensuring smooth patient transitions. VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed
    Show more Show less
    19 mins
  • Beyond the Formulary: Evolving Enterprise P&T Committees

    Beyond the Formulary: Evolving Enterprise P&T Committees
    Nov 11 2025

    Pharmacy and Therapeutics (P&T) committees historically operated at the individual hospital level but have evolved into enterprise-wide governance programs due to health system expansion, unprecedented clinical and financial complexity of care, and the emergence of high impact and novel therapeutics.

    To address this, the Vizient Center for Pharmacy Practice Excellence convened an expert panel that concluded health system enterprise P&T committees are uniquely positioned to balance clinical value with financial stewardship and minimize practice variation. They issued best practice considerations representing a dynamic framework designed to evolve alongside emerging therapies, evolving technologies, and the ongoing transformation of health systems.

    Joining us today are two members of the expert panel. We have Connor Hanrahan, AVP, enterprise pharmacy services, medication outcomes and stewardship with Intermountain Health and Prabashni Reddy, who at the time of the panel was the executive director of medication use and policy at Mass General Brigham.

    Guest speakers:

    Prabashni Reddy, RPh, PharmD, MMedSc (former) Executive Director of Medication Use and Policy

    Mass General Brigham

    Connor Hanrahan, PharmD, MHA, MS, BCPS, CPHQ AVP, Medication Policy, Outcomes, and Stewardship

    Intermountain Health, Enterprise Pharmacy Services

    Host:

    Kerry Schwarz, PharmD, MPH 

    Senior Clinical Manager, Evidence-Based Medicine and Outcomes

    Center for Pharmacy Practice Excellence (CPPE)

    Show Notes:

    [01:02-03:38] The value Prabashni and Conor saw in joining the expert panel

    [03:39-05:33] What Prabashni and Conor learned from interactions during the expert panel

    [05:34-10:55] Intriguing actionable enterprise P&T program insights panelists brought to the table that listeners can use

    [10:56-14:01] Use of criteria and principles to create successful and broadly applicable best practices

    [14:56-16:00] How our listeners can put this panel's best practices into action

    VerifiedRx Listener Feedback Survey:

    We would love to hear from you - Please click here

    Subscribe Today!

    Apple Podcasts

    Spotify

    YouTube

    RSS Feed
    Show more Show less
    17 mins
  • Challenges with AI in Pharmacy

    Challenges with AI in Pharmacy
    Oct 28 2025

    Artificial intelligence, or, AI is on everyone's minds, and we're all still figuring out how to trust it, teach it, and use it responsibly. Today we take a deep dive into how AI is affecting the education of current and future pharmacy students. With us is Jennifer Trujillo, associate Dean for education and professor in the Department of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences on the University of Colorado Anschutz Medical Campus in Aurora, Colorado, and Logan Tinsen, the clinical pharmacy manager and residency program director at Benefis Hospital in Great Falls, Montana.

    Guest speakers:

    Jennifer Trujillo, PharmD, BCPS, CDCES, BC-ADM Associate Dean for Education

    Professor, Department of Clinical Pharmacy

    Skaggs School of Pharmacy and Pharmaceutical Sciences

    University of Colorado Anschutz Medical Campus

    Logan Tinsen, PharmD, FMPA Clinical Pharmacy Manager and Residency Program Director Benefits Hospitals

    Host: 

    Kerry Schwarz, PharmD, MPH 

    Senior Clinical Manager, Evidence-Based Medicine and Outcomes

    Center for Pharmacy Practice Excellence (CPPE)

    Show Notes:

    [01:02-03:45] Challenges with AI in pharmacy education

    [03:46-05:59] The AI adoption spectrum: Pitfalls of extremes between full and limited adoption

    [06:00-11:18] Approaches to pharmacy education in the early stages of AI

    [11:19-14:55] Guardrails and safeguards

    [14:56-16:29] Key takeaways about AI right now for pharmacy educators

    VerifiedRx Listener Feedback Survey:

    We would love to hear from you - Please click here

    Subscribe Today!

    Apple Podcasts

    Spotify

    YouTube

    RSS Feed
    Show more Show less
    17 mins
No reviews yet